BridgeBio Pharma Retained Earnings (Accumulated Deficit) 2018-2024 | BBIO
BridgeBio Pharma retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-2.669B, a 20.49% increase year-over-year.
- BridgeBio Pharma retained earnings (accumulated deficit) for 2023 were $-2.561B, a 33.49% increase from 2022.
- BridgeBio Pharma retained earnings (accumulated deficit) for 2022 were $-1.918B, a 33.49% increase from 2021.
- BridgeBio Pharma retained earnings (accumulated deficit) for 2021 were $-1.437B, a 61.68% increase from 2020.